Sodium stibogluconate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sodium stibogluconate
Systematic (IUPAC) name
2,4:2',4'-O-(oxydistibylidyne)bis[D-gluconic acid]
Clinical data
AHFS/ International Drug Names
Legal status POM (UK)
Routes IV only
CAS number 16037-91-5 N
ATC code P01CB02 QP51AB02
PubChem CID 16685683
DrugBank DB05630
ChemSpider 21106382 YesY
UNII V083S0159D N
KEGG D00582 YesY
NIAID ChemDB 007935
Chemical data
Formula C12H38Na3O26Sb2 
Mol. mass 910.9 g/mol
 N (what is this?)  (verify)

Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of drugs known as the pentavalent antimonials because they contain antimony in its oxidation state of 5. Sodium stibogluconate is marketed under the name Pentostam. In parts of the world resistance has limited the utility of sodium stibogluconate,[1] in which cases amphotericin or miltefosine is used instead.


Sodium stibogluconate is available in the United Kingdom as Pentostam, where it is manufactured by GlaxoSmithKline. It comes in 100 ml multi-dose glass bottles. It can be diluted with 5% dextrose if necessary for ease of administration. It is available in the United States on a named-patient basis from the Centers for Disease Control and Prevention (CDC).

The dose of sodium stibogluconate is 20 mg/kg per day given by slow intravenous infusion (at least five minutes with cardiac monitoring). The injection are stopped if there is coughing or central chest pain. The chemotherapeutic index was established by Leonard Goodwin during the Second World War when a treatment was urgently required for Allied troops during the invasion of Sicily.[2]

The maximum licensed dose is 850 mg per day, but most authorities now agree that there should be no maximum.[3]

The duration of treatment is usually 10 to 21 days and depends on the species of Leishmania and the type of infection (cutaneous or visceral).

Chemical structure[edit]

The chemical structure of sodium stibogluconate is somewhat ambiguous, and the structure shown above is idealized. Its solutions may contain multiple antimony compounds, although this heterogeneity may be unimportant. It has been speculated that the active species contains only a single antimony centre.[4]

Side effects[edit]

Sodium stibogluconate is exceedingly phlebotoxic. One of the practical problems is that after a few doses it can become exceedingly difficult to find a vein in which to inject the drug. The insertion of a PICC does not prevent the problem and can instead exacerbate it: the entire vein along the course of the PICC line can become inflamed and thrombose. Large doses of sodium stibogluconate are often administered as dilute solutions

Pancreatitis is a common problem and the serum amylase or lipase should be monitored twice weekly; there is no need to stop treatment if the amylase remains less than four times the upper limit of normal; if the amylase rises above the cut-off then treatment should be interrupted until the amylase falls to less than twice the upper limit of normal, whereupon treatment can be resumed. Cardiac conduction disturbances are less common, but ECG monitoring while the medicine is injected is advisable and changes quickly reverse after the drug is stopped or the infusion rate is decreased.

The drug can be given intramuscularly but is exceedingly painful when given by this route. It can also be given intralesionally when treating cutaneous leishmaniasis (i.e., injected directly into the area of infected skin) and again, this is exceedingly painful and does not give results superior to intravenous administration.

Sodium stibogluconate can also cause a reduced appetite, metallic taste in mouth, nausea, vomiting, diarrhoea, headache, tiredness, joint pains, muscle aches, dizziness, and anaphylaxis.


  1. ^ Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M, Rosen BP (1996). "Trypanothione Overproduction and Resistance to Antimonials and Arsenicals in Leishmania" (pdf). PNAS 93 (19): 10383–10387. PMC 38393. PMID 8816809. 
  2. ^ "Leonard Goodwin - Telegraph". The Daily Telegraph. 14 January 2009. Retrieved 2009-01-18. 
  3. ^ Murray HW, Berman JD, Davies CR, Saravia NG (2005). "Advances in Leishmaniasis". Lancet 366 (9496): 1561–1577. doi:10.1016/S0140-6736(05)67629-5. PMID 16257344. 
  4. ^ Frézard F, Demicheli C, Ribeiro PR (2009). "Pentavalent Antimonials: New Perspectives for Old Drugs" (pdf). Molecules 14 (7): 2317–2336. doi:10.3390/molecules14072317. PMID 19633606.